CMS Removed Medicare Pathways for Breakthrough Devices
The federal agency ended expedited payment eligibility for new medical devices in August 2026.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Should medical devices receive expedited Medicare funding without proving substantial clinical improvement over existing alternatives?
The Centers for Medicare and Medicaid Services finalized the removal of special payment pathways for FDA-designated breakthrough devices in August 2026. This policy change eliminates previous provisions that allowed devices to qualify for add-on payments without proving substantial clinical improvement.
Why it matters
The removal of these pathways mandates that new medical technologies must now meet stricter criteria to receive supplemental Medicare coverage. This shift reverses a policy that prioritized rapid access for innovative devices since 2020.
STAT's Breakthrough Device Tracker has captured nearly 800 devices since 2022. Beginning in October 2026, new breakthrough-designated devices will no longer qualify for the special add-on payment treatment previously available under the program.
The players
Centers for Medicare and Medicaid Services
This federal agency is responsible for administering Medicare, Medicaid, and the Children's Health Insurance Program in the United States.
FDA
The Food and Drug Administration is a federal agency responsible for protecting public health by ensuring the safety of medical devices and other consumer products.
STAT
This news organization focuses on health, medicine, and scientific discovery and maintains the Breakthrough Device Tracker.
The details
The now-repealed policy previously allowed devices with breakthrough status to bypass requirements to demonstrate substantial clinical improvement or novelty when seeking Medicare add-on payments. The affected category includes a wide range of innovations such as urinary tract infection diagnostic panels, triage algorithms, and complex thrombectomy robots.
Timeline
2020: Breakthrough devices first gained access to the special Medicare payment pathways.
2022: STAT's Breakthrough Device Tracker began monitoring device statuses.
August 2026: The Centers for Medicare and Medicaid Services finalized the removal of the payment pathways.
October 2026: Special Medicare payment eligibility for new breakthrough-designated devices officially ends.
Market Landscape
This policy adjustment alters the financial incentives within the FDA breakthrough device designation program by removing expedited payment guarantees. It forces manufacturers to reconcile their development roadmaps with a landscape that no longer simplifies entry into the Medicare reimbursement system.
Patients and healthcare providers may see changes in the availability of certain cutting-edge medical technologies as manufacturers adjust to the new payment environment. Hospitals will need to evaluate the reimbursement viability of new diagnostic and surgical tools without the supplemental payment support previously guaranteed to breakthrough devices.
The takeaway
Innovation strategies for medical companies must now focus on proving substantial clinical improvement to secure Medicare coverage. This change highlights a broader regulatory shift toward prioritizing clinical evidence over rapid market entry for high-cost devices.
What happens next
New breakthrough-designated devices will be ineligible for special Medicare payment treatment starting in October 2026.
Further reading
Explore deeper insights into evolving regulations on the Healthcare sector page.
Source note: This article includes information reported by STAT.
Live Poll
Should medical devices receive expedited Medicare funding without proving substantial clinical improvement over existing alternatives?
